Streetbeat News

INVO

INVO Bioscience, Inc.

https://www.invobio.com

Industry

Medical - Devices

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

Open

0.86

Mkt cap

3.3M

Volume

124K

High

0.88

P/E Ratio

1.21

52-wk high

3.50

Low

0.82

Div yield

N/A

52-wk low

0.63

INVO Bioscience has announced a corporate name change to NAYA Biosciences. The company will begin trading under the new symbol 'NAYA' starting October 22.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 1:03 pm

The article highlights significant pre-market movements in health care stocks on Wednesday. Notable gainers include Biodexa Pharmaceuticals, Carmell, Tempest Therapeutics, NovoCure, NeuroBo Pharmaceuticals, and Windtree Therapeutics. On the losing side, Novavax, Assembly Biosciences, Dogwood Therapeutics, INVO Bioscience, NewGenIvf Group, and ABVC BioPharma experienced declines.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 12:10 pm

INVO BioScience, Inc. (NASDAQ:INVO) shares surged after announcing a merger with NAYA Biosciences. The combined company will focus on fertility, oncology, and autoimmune diseases, and plans to rebrand as Naya Biosciences with a new ticker 'NAYA'.

Portfolio Pulse from Erica Kollmann

October 14, 2024 | 9:38 pm

The article reports on the after-market movements of several healthcare stocks. Gritstone Bio, Palatin Techs, GRAIL, Cutera, Oragenics, and Aura Biosciences saw gains, while INVO Bioscience, Dogwood Therapeutics, Inhibikase Therapeutics, Carmell, Sera Prognostics, and Biofrontera experienced losses.

Portfolio Pulse from Benzinga Insights

October 14, 2024 | 8:31 pm

Several health care stocks experienced significant intraday movements on Monday. Notable gainers included Tevogen Bio Holdings, INVO Bioscience, and Longboard Pharmaceuticals, while Molecular Templates and Trinity Biotech were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 14, 2024 | 4:30 pm

INVO BioScience shares rose following the announcement of its completed merger with NAYA Biosciences.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 3:51 pm

INVO Bioscience has completed its merger with NAYA Biosciences. The combined entity will be renamed NAYA Biosciences and will trade on NASDAQ under the ticker 'NAYA'. The company will focus on fertility, oncology, and autoimmune diseases.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 1:25 pm

INVO BioScience reported a Q2 EPS of $(0.62), an improvement from $(3.06) year-over-year. Revenue increased to $1.826 million from $315,902 YoY.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 1:08 pm

Merck & Co., Inc. (NYSE:MRK) shares fell 10% after the company reported second-quarter financial results and cut its FY24 adjusted EPS guidance below estimates. Despite beating revenue and EPS estimates, the guidance cut led to a sharp decline. Other stocks such as Imunon, Inc. (NASDAQ:IMNN) and JetBlue Airways Corporation (NASDAQ:JBLU) saw significant gains due to positive news, while QXO, Inc. (NASDAQ:QXO) and VBI Vaccines Inc. (NASDAQ:VBIV) experienced substantial losses.

Portfolio Pulse from Avi Kapoor

July 30, 2024 | 5:53 pm

Pitney Bowes shares surged over 12% in pre-market trading after selling part of its e-commerce business to Stord. Other notable pre-market movers include Cognition Therapeutics, Longeveron, and Abbott Laboratories, among others.

Portfolio Pulse from Avi Kapoor

July 29, 2024 | 9:26 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.